Race for better treatment in Tough-to-Treat blood cancer
NCT ID NCT06122389
Summary
This study aims to find out if a new drug called SHR2554 works better than an existing drug called chidamide for patients with a type of blood cancer called peripheral T-cell lymphoma (PTCL) that has come back or stopped responding to prior treatment. About 130 adults who have already tried at least one other treatment will be randomly assigned to receive one of the two drugs. The main goal is to see which drug keeps the cancer from getting worse for a longer period of time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY PTCLT WITH AT LEAST ONE LINE OF PRIOR SYSTEMIC THERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.